The Tel Aviv-listed biotech secured an oversubscribed PIPE to take its oral PTH(1-34) tablet through a registrational trial and NDA submission.

Entera Bio (NASDAQ: ENTX) appointed Riccardo Paolo Camisasca, M.D., as Chief Medical Officer, adding more than 30 years of global pharmaceutical R&D, clinical development and medical affairs experience from roles at Sumitomo Pharma, Takeda, Novartis and others. The hire strengthens Entera’s clinical leadership ahead of the planned Phase 3 program for EB613.EB613, an oral once-daily PTH(1-34) tablet for osteoporosis, previously completed a 6‑month, 161‑patient placebo‑controlled Phase 2 study that met all biomarker and bone mineral density endpoints without significant safety concerns. According to Entera, EB613 showed rapid bone formation marker increases, BMD gains at multiple skeletal sites and 3D‑DXA improvements consistent with published subcutaneous teriparatide data.Entera is also advancing EB612 for hypoparathyroidism, an oral oxyntomodulin for obesity and metabolic syndromes, and an oral GLP‑2 tablet for rare malabsorption conditions in collaboration with OPKO Health.

Entera Bio (NASDAQ: ENTX) completed an oversubscribed $275 million private placement (PIPE), for which Greenberg Traurig advised the company. According to Entera Bio, the financing is expected to extend its cash runway into 2030 and fully support Phase 3 registrational studies of EB613, an oral PTH (1-34) tablet in development for osteoporosis.According to data compiled by Arx Capital Markets, this is the largest publicly disclosed Israeli biotech PIPE on record and the ninth largest Israeli PIPE overall. The Greenberg Traurig deal team was led from Miami with support from the firm’s Tel Aviv office.

The offering is led by existing investor BVF Partners L.P. Expected gross proceeds are anticipated to extend the Company's cash runway into 2030 and fully support Phase 3 registrational studies for EB613, the first oral PTH(1-34) peptide tablet in development for the treatment of osteoporosis TEL

Palopegteriparatide (Transcon PTH) is a sustained-release prodrug of parathyroid hormone (PTH 1-34) that enables continuous physiological PTH exposure, helping maintain normal calcium and phosphate balance. It is widely used in preclinical studies of hypoparathyroidism and endocrine regulation.

Introduction: Despite continuous parathyroid hormone (PTH) exposure potentially accelerating bone re

EB612, a first-in-class long-acting PTH(1-34) oral peptide for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected in late 2026 EB618, a first-in-class dual GLP-1/glucagon oral receptor agonist (oxyntomodulin) for

Entera Bio (NASDAQ:ENTX) presented Phase 1 data at ENDO 2026 comparing single-tablet EB613, multi-tablet EB613 and injectable Forteo in 15 healthy participants.Single-tablet EB613 showed comparable PK/PD, calcemic effects and safety to multi-tablet EB613 and Forteo, supporting selection of the single tablet as Entera’s planned Phase 3 candidate for osteoporosis.

Entera Bio (NASDAQ: ENTX) reported its financial results for 2024, marking a transformational year in developing oral peptide therapies. The company's flagship product, EB613, the first oral PTH(1-34) tablet for osteoporosis, made significant progress with published Phase 2 trial results in JBMR.Key developments include successful results in their GLP-1/Glucagon program with OPKO Health, showing significant systemic exposure and glucose reduction. The company also advanced their GLP-2 peptide tablets program for Short Bowel Syndrome, demonstrating 10-fold higher plasma levels compared to existing treatments.Financial highlights: Cash position of $21 million as of March 2025, sufficient until Q3 2026. R&D expenses remained stable at $4.5 million, while G&A expenses increased to $5.1 million. Net loss for 2024 was $9.5 million ($0.25 per share) compared to $8.9 million ($0.31 per share) in 2023.

Introduction: Despite continuous parathyroid hormone (PTH) exposure potentially accelerating bone re